Critically ill patients with COVID-19 treated with an arthritis drug that reduces inflammation are significantly more likely to have improved outcomes, an international study has found. The early findings, which are yet to be published, come from the REMAP-CAP trial, led by Imperial College London and the Intensive Care National Audit & Research Centre (ICNARC) […]
Read More… from Arthritis drug effective in treating sickest COVID-19 patients









